Daiwa Securities Group Inc. Insmed Inc Transaction History

Daiwa Securities Group Inc.

$21.6 Billion
Q3 2024

A detailed history of Daiwa Securities Group Inc. transactions in Insmed Inc stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 635 shares of INSM stock, worth $44,450. This represents 0.0% of its overall portfolio holdings.

Number of Shares

635

Previous 585 8.55%

Holding current value

$44,450

Previous $39,000 17.95%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$62.0 - $79.01 $3,100 - $3,950	50 Added 8.55%	635 $46,000
Q2 2024 Aug 07, 2024	BUY	$22.0 - $69.71 $880 - $2,788	40 Added 7.34%	585 $39,000
Q4 2022 Feb 06, 2023	BUY	$16.98 - $23.15 $1,698 - $2,315	100 Added 22.47%	545 $11,000
Q2 2022 Aug 09, 2022	BUY	$17.07 - $25.71 $1,707 - $2,571	100 Added 28.99%	445 $9,000
Q4 2021 Feb 03, 2022	SELL	$25.89 - $33.45 $1,294 - $1,672	-50 Reduced 12.66%	345 $9,000
Q3 2021 Nov 05, 2021	BUY	$22.46 - $29.47 $4,289 - $5,628	191 Added 93.63%	395 $11,000
Q1 2021 May 03, 2021	BUY	$32.28 - $44.3 $387 - $531	12 Added 6.25%	204 $7,000
Q4 2020 Feb 04, 2021	SELL	$31.45 - $40.54 $12,076 - $15,567	-384 Reduced 66.67%	192 $6,000
Q3 2020 Nov 02, 2020	BUY	$26.0 - $34.5 $1,872 - $2,484	72 Added 14.29%	576 $19,000
Q4 2019 Jan 31, 2020	SELL	$16.12 - $24.98 $725 - $1,124	-45 Reduced 8.2%	504 $12,000
Q2 2019 Jul 24, 2019	BUY	$23.0 - $32.19 $1,288 - $1,802	56 Added 11.36%	549 $14,000
Q1 2019 Apr 26, 2019	BUY	$13.91 - $31.15 $973 - $2,180	70 Added 16.55%	493 $14,000
Q1 2018 May 02, 2018	BUY	$21.69 - $32.99 $9,174 - $13,954	423 New	423 $10,000

Others Institutions Holding INSM

# of Institutions

467

Shares Held

182M

Call Options Held

2.27M

Put Options Held

3.33M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $9.48B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.

Account

Daiwa Securities Group Inc. Insmed Inc Transaction History